Analysis of genetic polymorphism relating to interstitial lung disease events in patients with advanced pancreatic cancer receiving gemcitabine plus erlotinib

Trial Profile

Analysis of genetic polymorphism relating to interstitial lung disease events in patients with advanced pancreatic cancer receiving gemcitabine plus erlotinib

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 10 Oct 2017

At a glance

  • Drugs Erlotinib (Primary) ; Gemcitabine (Primary)
  • Indications Pancreatic cancer
  • Focus Adverse reactions; Pharmacogenomic
  • Most Recent Events

    • 01 Sep 2015 Status changed from recruiting to active, no longer recruiting, as reported by University Hospital Medical Information Network - Japan record.
    • 05 Oct 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top